Bogle Investment Management’s Corcept Therapeutics CORT Stock Holding History

Bogle Investment Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-140,512	Closed	-$2.45M	–	168
2020 Q3	$2.45M	Buy	+140,512	New	+$2.24M	0.72%	75
2018 Q1	–	Sell	-705,941	Closed	-$12.7M	–	318
2017 Q4	$12.7M	Buy	705,941 +17,009	+2%	+$308K	0.94%	34
2017 Q3	$13.3M	Buy	688,932 +18,547	+3%	+$277K	0.91%	30
2017 Q2	$7.91M	Hold	670,385	–	–	0.58%	76
2017 Q1	$7.35M	Buy	670,385 +338,438	+102%	+$2.97M	0.51%	78
2016 Q4	$2.41M	Buy	+331,947	New	+$2.6M	0.17%	158
2015 Q4	–	Sell	-196,193	Closed	-$737K	–	386
2015 Q3	$737K	Sell	196,193 -46,661	-19%	-$237K	0.05%	283
2015 Q2	$1.46M	Buy	+242,854	New	+$1.49M	0.11%	220

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bogle Investment Management's CORT Position: Q4 2020 in Review

Bogle Investment Management sold out of Corcept Therapeutics (CORT) in Q4 2020, closing a stake of 140,512 shares — an estimated $2.45M sold.

Bogle Investment Management first reported a position in CORT in Q2 2015 and held it in 8 quarters. The position peaked at $13.3M in Q3 2017. 226 funds tracked by Wall St. Rank hold CORT as of Q4 2020.

Bogle Investment Management reported no remaining Corcept Therapeutics position as of Q4 2020 after selling out during the quarter.
Bogle Investment Management sold 140,512 Corcept Therapeutics shares in Q4 2020, an estimated $2.45M.
Bogle Investment Management first reported a position in Corcept Therapeutics in Q2 2015 and held it in 8 quarters.
Bogle Investment Management's Corcept Therapeutics position peaked at $13.3M in Q3 2017.
226 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2020.

Based on Bogle Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.